糖尿病用薬剤 ―必要な薬剤と不要な薬剤

DOI Web Site Web Site 参考文献14件
  • 浜 六郎
    NPO法人医薬ビジランスセンター（薬のチェック）

書誌事項

タイトル別名
  • Essential and unnecessary medicines for diabetes
  • トウニョウビョウ ヨウヤクザイ : ヒツヨウ ナ ヤクザイ ト フヨウ ナ ヤクザイ

この論文をさがす

抄録

Diabetes is a disease with insufficient effects of insulin which acts on more than 100 kinds of genes and essential for metabolism of nutrients including carbohydrates, protein and lipids and for normal function of each cell in the body. Generally believed endpoint“control blood glucose level normal”is misleading. True endpoint is to live long by relieving the deficiency of insulin effects for nutrients to be appropriately utilized to maintain normal function of the body and to reduce complications. The outcome of clinical trials must be all-cause mortality because cause-specific mortality or incidence of diseases may miss the adverse effects especially on cancer incidence leading to shortening of overall survival. Insulin but not insulin analog is the only recommended medicine for diabetes tobe used if appropriate energy of carbohydrate restriction diet, moderate exercise and sufficient sleep without sleeping pills were ineffective. Sulfonyl urea（SU）increases insulin secretion by closing K ATP channels in pancreatic β cells but induces secondary failure without proof of prolongation oflife. Biguanide is an inhibitor of mitochondrial chain complex I（a mitochondrialpoison）and open K ATPchannels leading to reduction of insulin secretion（oppositeto SU）and recover the sensitivity to insulin. It may be beneficial for only thosewith 30 or more of BMI. The incretin-related agents（DPP-4 inhibitor and GLP-1 analogue）show carcinogenicity in both animal toxicity studies and clinical trials. The long term prognosis of incretin-related agents and SGLT-2 inhibitors are not proved because of the serious methodological failures.y

収録刊行物

  • 脂質栄養学

    脂質栄養学 26 (1), 59-74, 2017

    日本脂質栄養学会

参考文献 (14)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ